Cancer is currently the leading cause of death worldwide according to the World
Health Organization1. In 2007, approximately 7.9 million people died of cancer
and over 12 million new cases are diagnosed each year. As a result, cancer is the
world’s most costly disease2. In terms of disability and years of life lost,
cancer’s global economic toll was $895 billion (1.5% of world GDP) in 2008. In the
U.S., the National Institutes of Health estimates overall cancer costs in 2010 at
$264 billion, i.e. $103 billion for direct medical costs and $161 billion due to
indirect costs associated with loss of productivity to illness and death3.
Almost everyone has experienced the devastating heartache of cancer either as a
patient or with the loss of loved family members or close friends.
Bexion's Elegant Solution
New research findings on BXQ-350 nanovesicles for the diagnosis and treatment of
cancer in laboratory animals are very promising. The anti-cancer
activity of BXQ-350 nanovesicles was discovered and first published by researchers
at Cincinnati Children’s Hospital Medical Center4. These researchers
showed that BXQ-350 nanovesicles killed human brain, nerve, and breast cancer
cells in test tubes. They also showed that BXQ-350 nanovesicles stopped
the growth of human brain and nerve cancers transplanted into mice with no observable adverse
effects after 5 weeks of dosing.
Additional unpublished research sponsored by Bexion Pharmaceuticals has shown that
BXQ-350 nanovesicles kills over 60 different types of human cancer cells in
test tubes. By adding a dye to BXQ-350 nanovesicles, the Bexion scientists
have been able to visualize penetration of the drug into several different types
of cancers in rats and mice including pancreas, breast and brain cancers, with no
penetration into healthy tissues. Of importance, BXQ-350 treatment significantly
increased (doubled) survival times for many mice with either brain
or pancreatic cancer. Sixty-seven (67%) of mice with pancreatic cancer
survived with BXQ-350 treatment. In total, BXQ-350 nanovesicles have been shown
to be highly effective for treating cancer in 7 different mouse cancer models. In
these extensive pre-clinical (animal) studies, there have been no observable significant
adverse effects on animal behavior, body weight, food consumption, organ weights,
clinical pathology blood tests, or tissue pathology.
As a result of these exciting pre-clinical findings, the National Cancer Institute
(NCI) has selected Bexion Pharmaceuticals as a collaborative research partner to
advance research on BXQ-350 nanovesicle treatment of cancer. The purpose of this
partnership is to speed the generation of scientific data needed for filing an investigative
new drug (IND) application to the U.S. Food & Drug Administration (FDA).
If similar results are found in human cancer patients, BXQ-350 nanovesicle treatment
of cancer could provide considerable potential benefits to affected patients.
- World Health Organization. Quick cancer facts. WHO, Geneva, Switzerland http://www.who.int/cancer/en/
- Marchione, M. Cancer is the world’s costliest disease. Associated Press. August 17, 2010 http://www.foxnews.com/health/2010/08/17/report-cancer-worlds-costliest-disease/
- American Cancer Society. Cancer facts and figures 2010. ACS, Atlanta, GA, USA, 2010. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010
- Qi X., Chu Z., Mahller Y., Stringer K., Witte D., Cripe T. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal Saposin C protein. Clin Cancer Res. 15(18): 5840-5851, 2009.